Completed PHASE2 INTERVENTIONAL 1-arm NCT01815528

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes

Sponsor: JSehouli

Conditions Recurrent Epithelial Ovarian Cancer

Interventions Catumaxomab

Updated 5 times since 2017 Last updated: Feb 17, 2015 Started: Mar 31, 2013 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Recurrent Epithelial Ovarian Cancer and is currently completed. JSehouli leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

JSehouli

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany